“We are very impressed with Syngene’s professionalism, commitment to scientific excellence, and ability to deliver high-quality work on time,” said Allan Wehnert, CEO & Founder of Orocidin. “This ...

Looking for the best Microsoft Edge video downloader? We’ve got you covered! We found a few reliable extensions and apps that support multiple video formats and high quality. Some support quick ...

Guidance for 2025 pointed to revenues growth at a high single-digit percentage and core earnings at a low double-digit, both at constant exchange rates. The shares rose 565.3p to 11,691.3p despite ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...

GSK today increased its 2031 sales outlook to more than £40 billion, up from £38 billion amid stronger progress in its late-stage drugs pipeline. Total 2024 sales in GSK’s annual results published ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.40. The company’s shares opened today ...

GSK said it now e American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast.

Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline. It came as the boss of the London-listed firm cheered an “excellent ...

Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline. It came as the boss of the London-listed firm cheered an “excellent” ...

Below is an image shared on the Nike SNKRS app yesterday that broke down the NBHD doors stocking the limited “Bred” Air Jordan 1 High ’85 next month. A majority of the shops are located in ...

At the J.P. Morgan Healthcare conference earlier this month, Emma Walmsley, CEO of GSK, a leading vaccine maker, said she'd "wait and see what the facts are" before predicting what Kennedy would do.